TAC1抗体

+ +

•  

   

     Western blot analysis of GAL4 DNA Binding Domain in Recombinant BD protein lysates using GAL4 DNA Binding Domain antibody.    

  
  

The TAC1 antibody targets proteins encoded by the tachykinin precursor 1 (*TAC1*) gene, which is critical in synthesizing neuropeptides such as substance P (SP), neurokinin A (NKA), and related peptides. These peptides belong to the tachykinin family, known for their roles in neurotransmission, inflammation, and pain signaling. TAC1-derived peptides bind to G protein-coupled receptors (NK1R, NK2R, NK3R), influencing processes like nociception, smooth muscle contraction, and immune responses.

TAC1 antibodies are essential tools for detecting and quantifying TAC1-derived peptides in research. They are widely used in immunohistochemistry, Western blotting, and ELISA to study expression patterns in neuronal tissues, immune cells, and cancer microenvironments. Dysregulated TAC1 expression is linked to chronic pain syndromes, inflammatory diseases (e.g., asthma, arthritis), and cancer progression, making these antibodies valuable for mechanistic and therapeutic studies.

Antibodies against TAC1 are typically designed to recognize specific epitopes within precursor proteins or mature peptides. Monoclonal antibodies offer high specificity, while polyclonal variants may detect multiple isoforms. Validation includes knockout controls or peptide-blocking assays to confirm target specificity. Recent applications explore TAC1’s role as a biomarker or therapeutic target, particularly in pain management and oncology, driving interest in developing neutralizing antibodies or receptor inhibitors.